ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
FORMULATION FORUM - Lymphatic versus Portal Drug Delivery: An Understanding of Drug Oral Absorption & Food Effect
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
TREND SCOUTING - Anticipating the Future of Pharma
Gregor Deutschle says by implementing a strategic, considerate, and proactive approach to trend forecasting, pharmaceutical service providers can effectively weigh the benefits and challenges of potential trends, invest in those most aligned with customer needs, and avoid the allocation of time and resources in trends that will not provide meaningful ROI.
ECO-DESIGN TOOL - How Life Cycle Assessment is Transforming Drug Delivery Device Sustainability
Alex Fong, MBA, believes in an era where sustainability is not just a goal but a necessity, LCA has the potential to reshape how the pharmaceutical industry approaches this multifaceted issue.
DRUG DEVELOPMENT - Improving Bioavailability & Solubility in OSDs
Hibreniguss Terefe, PhD, explores the options available to improve bioavailability and solubility and provides guidance to support decision-making when designing oral formulations for poorly soluble drug candidates in early development.
CELL-FREE GENE SYNTHESIS - Eliminating Critical Bottlenecks in Genetic Medicine Development
Marc Unger explores the market trends, challenges, and opportunities new DNA production technologies provide to accelerate genetic advances in healthcare.
EXECUTIVE INTERVIEW - Lonza: Driving Innovation & Sustainability: CDMO Trends & the Future of ADCs
Sebastian Stenderup, Executive Director, Head of Commercial EMEA, Lonza, discusses some of the trends CDMOs are currently facing, from the growth of ADCs to the importance of sustainability, and how his company is responding to them.
CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials
Neil Vivian, MSc, says advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.
EXECUTIVE INTERVIEW - How Vetter’s Expansion of its Senior Management Team Aligns With Prioritization of Strategic Growth
Vetter’s leadership discusses the company’s vision for strategic restructuring, their insights on Contract Development and Manufacturing trends in 2025, and what this strategic change means for the sustainable growth of the company and its global expansion.
ORAL DOSAGE FORMS - The Future of Oral Dosage: Innovations, Challenges & the Path Forward in 2025
Sébastien Croquet explores the latest industry challenges, cutting-edge manufacturing techniques, and patient needs defining today’s oral delivery methods, and breaks down some of the ways drug producers can ride, or even define, the next wave of oral drug delivery.
RUV CLOSURES - Daikyo PLASCAP® RUV Closures: Securing Annex 1 Compliance Through Contamination-Controlled Closure Innovation
Jim Thompson, MBA, explains how through a long-standing partnership with Daikyo, West can answer multi-faceted vial stoppering and capping challenges with both Crystal Zenith® (CZ) polymer nested vials and PLASCAP® Ready-to-Use Validated (RUV) press-fit closures.
SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
LEADERSHIP PANEL - What Will Have the Most Impact on Drug Development in 2025?
Contributor Cindy H. Dubin asked several life science leaders what they believe will have the greatest impact on drug development in 2025.
FORMULATION FORUM - Nanoparticle Technologies for Oral Delivery of Peptides & Proteins
Jim Huang, PhD, and Shaukat Ali, PhD, examine various nanoparticle technologies in oral delivery of large molecules.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
How to Choose the Right CDMO for Your Pharmaceutical Project
This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.
Understanding the Foundation of LNP Formulation Success
Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….
Lyophilization Development: Quality by Design Approach
Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……
Choosing the Right Particle for Your Nanomedicine Application
Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….
Join us for the inaugural Quotient Sciences Capability Expo, hosted at our state-of-the-art Garnet Valley facility.
This unique event offers a behind-the-scenes look at how we support molecules from preclinical stages through to commercial manufacturing…..
Have expert content to share? Contact us
EXCLUSIVE WHITEPAPERS
WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations
By overcoming key challenges 3D screen printing is unlocking new possibilities in drug development and manufacturing.
WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide
Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug…
CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form
In this CPHI Award-winning case study, learn how Adare scientists took the alternative sprinkle version out of the lab and into the hands of patients.
ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products
Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs.
WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers
This whitepaper explores the various types of technology transfer from preclinical to commercial stages and successful strategies to foster innovation.
EXCLUSIVE WEBINARS
WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
WEBINAR - ABISOL Emulsion Preconcentrate Kit & ABISORB-DC Excipient System for Tableting Lipids
ABITEC Technical Business Director, John Tillotson, RPh, PhD, discusses ABITEC’s latest products: The ABISOL Emulsion Preconcentrate kit for the easy formulation of emulsified drug delivery systems and the….
WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond
Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.
MARKET NEWS & TRENDS
Gattefossé Advances Animal Health Through Science & Innovation
Gattefossé mission, advancing science for well-being, reflects its core engagement: to provide expert, customized, and responsible solutions in Personal Care and Pharmaceuticals, including animal health.…
MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital
MoonLake Immunotherapeutics recently announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in…
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of an Oral Once-Daily Treatment for Obstructive Sleep Apnea
Incannex Healthcare Inc recently announced it has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of…
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial & Advance Regenerative Cell Therapy Pipeline
Neurona Therapeutics, a clinical-stage, privately held biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an…
BASF Launches Aroma Ingredients With Reduced Product Carbon Footprints
BASF Aroma Ingredients has successfully launched L-Menthol FCC rPCF as its first product with a reduced Product Carbon Footprint (rPCF). Further rPCF product launches are…
Greenwich LifeSciences Announces Positive Immune Response Data From Phase 3 Clinical Trial
Greenwich LifeSciences, Inc. recently announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the…
Antag Therapeutics Initiates Phase 1a Trial of a First-in-Class GIPR Antagonist to Address Key Gaps in Obesity Treatment
Antag Therapeutics recently announced the initiation of its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist. AT-7687 is…
Bend Bioscience Adds Commercial Spray Drying & Granulation in Georgia
Bend Bioscience recently announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its 120,000-square-foot facility in Gainesville, GA. The…
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
Tiziana Life Sciences, Ltd. recently announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2…
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval
Denali Therapeutics Inc. recently announced the company’s initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for…
Atsena Therapeutics Announces $150M to Further Advance Ocular Gene Therapy Programs
Atsena Therapeutics recently announced the successful close of an oversubscribed $150-million Series C financing. The financing was led by Bain Capital’s Life Sciences team, with…
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
Revive Therapeutics Ltd. recently announce that further to its press release dated March 3, 2025, it has entered into an asset purchase agreement dated March…
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 & Nivolumab Plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Candel Therapeutics, Inc. recently announced the publication of a manuscript reporting the results of a Phase 1b clinical trial exploring safety and tolerability of the…
GRIN Therapeutics Receives Priority Medicines Designation From EMA for Radiprodil in the Treatment of GRIN-Related Neurodevelopmental Disorder
GRIN Therapeutics, Inc. recently announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company’s investigational, potent negative allosteric…
Moleculin Doses First Patient in Pivotal Adaptive Phase 3 MIRACLE Trial
Moleculin Biotech, Inc. recently announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known…
DDL Launches New GMP Lab for Drug Delivery Testing
DDL, a leading provider of package, product, and material testing services, recently announce the opening of a new Good Manufacturing Practice (GMP) laboratory dedicated to…
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Gyre Therapeutics recently announced that the National Medical Products Administration (NMPA) of the People’s Republic of China (PRC) has approved its clinical trial application for…
Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis Patient With TRE 515
Trethera Corporation recently announced clinical results from treating a patient with ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease) with TRE-515 under the…
Apollomics & LaunXP Announce Development & Commercialization Agreement for Vebreltinib
Apollomics Inc. and LaunXP International Co., Ltd. recently announced the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland…
NeOnc Technologies Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
NeOnc Technologies Holdings, Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100) for the treatment of pediatric-type…
